Objective: The aim of this study was to determine if premenopausal ovarian reserve is associated with susceptibility for atherosclerosis.
C ardiovascular disease remains the leading cause of mortality in postmenopausal women. 1 Coronary heart disease (CHD) due to atherosclerosis accounts for most of those deaths, with more than 50% of women experiencing sudden cardiac death. Furthermore, many of these women succumb without previously reported symptoms. 2 Because the underlying atherosclerosis probably develops over a period of decades, these data emphasize the need for improved methods of assessment that would allow earlier identification of women at risk for CHD. However, gaps in knowledge still exist regarding the initiation and progression of atherosclerosis in this population. For example, the Framingham Risk Score has been reported to underestimate risk in perimenopausal and early postmenopausal women. Hence, data from a group of young (È55 y), nondiabetic, postmenopausal women revealed detectable coronary artery calcium, indicative of subclinical atherosclerosis, despite having a low Framingham risk score. 3 Although evidence is accumulating in support of an interventional Bwindow of opportunity[ for estrogen treatment in the reduction of CHD in early postmenopausal women, 4 the nature of the association between CHD risk and loss of ovarian function (menopause) is still controversial. For example, in a meta-analysis of 18 studies, no relationship between postmenopause status and cardiovascular disease was found, and only a modest effect of early menopause (surgical 9 natural) was observed. 5 Conflicting data on this subject may be due, in part, to the inability to account for the variability in type of Bmenopause[ being investigated, including natural versus surgical (hysterectomy with or without oophorectomy) and early (premature ovarian failure) versus later menopause. Furthermore, it has not been possible in most studies to account for variations in the length of the menopausal transition (2-10 years) or to account for women who may have experienced reproductive dysfunction prior to the menopausal transition. Data from women and nonhuman primates suggest that premenopausal ovarian function may affect risk for chronic disease postmenopausally. 6, 7 More precise estimations of ovarian reserve using antimüllerian hormone (AMH), along with application of improved clinical staging of reproductive aging using criteria such as those from Stages of Reproductive Aging Workshop criteria 8 for the classification of women in the menopausal transition, may increase understanding of the aforementioned relationships.
AMH is a protein hormone in the transforming growth factor-A family and is produced by the granulosa cells of small growing (preantral and small antral) follicles in the ovary of rodents and nonhuman and human primates. AMH is positively correlated with primordial follicle numbers (ovarian reserve) in both women 9, 10 and Old World nonhuman primates 11 (r 9 0.7 for both). Decreases in AMH parallel follicle loss as women approach menopause, 12 and AMH has been reported to fall to very low levels as early as 5 years before the final menstrual period. 13 Although AMH's main role is believed to be the regulation of primordial follicle recruitment, 14<17 recent reports in mice indicate that AMH may have neuroprotective effects in the brain. 18 It is not known currently whether AMH has direct effects on other nonovarian tissues.
The purpose of the study presented here was to determine retrospectively whether premenopausal ovarian reserve, as indicated by plasma AMH concentration, is associated with subsequent atherosclerosis progression. The data thus represent an opportunistic observation from a larger study designed to determine the effect of ovarian reserve on risk for chronic disease. 19 
METHODS

Study design and diet
Sixty-six female cynomolgus macaques (Macaca fascicularis; imported from the Institut Pertanian, Bogor, Indonesia) were used for this study. These monkeys are part of an ongoing study designed to investigate the effects of ovarian reserve on cardiovascular and metabolic disease risk. The study design has been described previously. 19 Briefly, adult status was confirmed by dentition and evidence of epiphyseal closure, and the mean age and body weight (BW) of the monkeys were 15 years (range, 7-21 y) and 3.1 kg, respectively. All monkeys were housed in social groups of two to four individuals and were fed a semipurified diet formulated to be similar to diets consumed by women in North America. The diet was prepared in the Wake Forest Primate Center diet laboratory and contained 0.20 to 0.28 mg cholesterol per calorie and derived 19% of its energy from protein (casein and lactalbumin), È35% from fat, and È47% from carbohydrates. The monkeys were fed 120 cal of diet/kg BW daily.
For the first 5 months of the study, monkeys were exposed to a moderate amount of cholesterol (0.20 mg/cal). Cholesterol content of the diet was then increased to 0.28 mg cholesterol per calorie for the remainder of the study. After consuming the diet for È7 months (baseline period), monkeys were randomized to one of three conditions: (1) bilateral ovariectomy (OVX; n = 17), (2) premenopausal (PRE, n = 20), or (3) premenopausal with reduced ovarian reserve (ROR; n = 29). After OVX, plasma concentrations of estradiol (E 2 ) were monitored to document completeness of the OVX (E 2 concentrations below the level of assay detection). Three monkeys were excluded from the original 20 monkeys in the OVX group because of resumption of intermittent menstrual bleeding and measureable E 2 concentrations, indicative of the presence of ectopic ovarian tissue. 20 ROR was achieved by the surgical placement of a biodegradable periovarian implant containing a compound that specifically targets primordial follicles (4-vinylcyclohexenediepoxide), thereby decreasing ovarian reserve and mimicking the early stages of the menopausal transition. 21 This procedure coincided with the OVX surgeries. Treatment with 4-vinylcyclohexenediepoxide reduced AMH by È56% (14.1 T 1.7 to 6.7 T 0.5 ng/mL) within 4 months, 19 which remained above the level of detection for the duration of the experiment.
After OVX and induction of ROR, monkeys consumed the Western diet for 26 months. The iliac artery was then biopsied to allow the measurement of atherosclerosis extent (plaque area, in mm 2 ) without killing the animal. The iliac artery was used because it provides an estimate of coronary artery atherosclerosis extent owing to its high correlation with coronary artery atherosclerosis (r 9 0.71). 22 All animal manipulations were approved by the Wake Forest University Animal Care and Use Committee and were conducted in accordance with state and federal laws and following the guidelines of the US Department of Health and Human Services.
Plasma measures
AMH and plasma lipid determinations were done after 5 months of consumption of the diet (baseline) and within 2 months before artery collection. Serum AMH was measured using enzyme-linked immunosorbent assay (DSL, Webster, TX; intra-assay coefficient of variation [CV], 4.53% at 13.62 ng/mL; interassay CV, 19.75% at 0.23 ng/mL, 11.42% at 9.61 ng/mL, and 11.27% at 1.89 ng/mL). Total plasma cholesterol (TPC) concentrations, high-density lipoprotein cholesterol (HDL-C) concentrations, and plasma triglyceride levels were determined in the Comparative Medicine Clinical Chemistry and Endocrinology Laboratory using reagents (ACE cholesterol, ACE HDL-C, and ACE triglycerides) and instrumentation (ACE ALERA autoanalyzer) from Alfa Wasserman Diagnostic Technologies (West Caldwell, NJ). TPC and HDL-C were standardized to calibrated controls from the Centers for Disease Control and Prevention, National Heart, Lung, and Blood Lipid Standardization Program. Intra-assay and interassay CVs were less than 5% for all analytes. Non-HDL-C, which approximates the sum of low-density lipoprotein (LDL) cholesterol and verylow-density lipoprotein cholesterol (VLDL-C), was calculated by subtracting HDL-C from TPC. Plasma glucose concentrations were determined by the glucose oxidase method using a Glucose Analyzer 2 (Beckman Instruments, Brea, CA). E 2 was measured during the follicular phase across two baseline menstrual cycles, approximately 4 and 5 months after arrival of monkeys from Indonesia. E 2 was measured from serum by a modification 23 of a commercially available radioimmunoassay from Diagnostic Products Corporation (Los Angeles, CA). Intra-assay and interassay CVs were less than 4% and 10%, respectively.
Measurement of atherosclerosis
The left common iliac artery was collected from all monkeys after consuming the diet for a total of È33 months (7 mo baseline plus 26 mo post-OVX). Once collected, the left common iliac artery was opened longitudinally, laid flat, fixed in 4% paraformaldehyde for 24 hours, and then transferred to 70% ethanol. After fixation, the artery was divided into the three equal segments and embedded in paraffin, and sections (4 Km) from each block were stained with Verhoeff-van Gieson stain. Images of arteries were digitally captured, and the extent of atherosclerosis (mm 2 ) was determined using methods published previously. 24 
Statistical analysis
For this investigation, the treatment groups (OVX, ROR, and PRE) were balanced before intervention at baseline for BW, AMH, and TPC/HDL-C ratio. To meet normality and equality of variance assumptions, atherosclerosis plaque area (mm 2 ) and AMH were square root (SQRT) transformed and the data were then back transformed for presentation. There were no significant differences in the square root of plaque extent among the three arterial blocks measured per left common iliac artery (block 1, 0.7 T 0.04; block 2, 0.67 T 0.05; block 3, 0.68 T 0.05; P = 0.22), and therefore, the mean of plaque area (mm 2 ) for all three blocks was used as the outcome variable for all further analysis of atherosclerosis extent. AMH for all monkeys measured at baseline was divided into tertiles with the following ranges: low AMH, 0.96 to 7.6 ng/mL; mid AMH, 7.71 to 14.4 ng/mL; and high AMH, 4.6 to 50.6 ng/mL. Atherosclerosis extent was also analyzed according to baseline median AMH within each treatment group. Statistical analysis was done using SAS 9.2 and the SAS-based software JMP version 9. General linear models were used to examine the differences in plaque area, plasma lipids, E 2 , and BW among tertiles of AMH as well as among treatment groups. A multivariate regression model was used to determine correlations among variables. The significance was set at P G 0.05.
RESULTS
Atherosclerosis extent is not affected by treatment but is predicted by baseline AMH
The common iliac artery was collected from all monkeys after consuming the diet for a total of È33 months (baseline plus posttreatment period). Mean plaque area did not differ among the treatment groups (OVX, 0.75 T 0.08 mm 2 ; ROR, 0.68 T 0.07 mm 2 ; PRE, 0.73 T 0.08 mm 2 ; P = 0.8 overall, nontransformed means; Fig. 1A ). Because the treatment groups were balanced before treatment according to baseline AMH, a procedure not done in previous studies, data were then analyzed to determine whether baseline AMH for all monkeys was associated with subsequent atherosclerosis extent. Atherosclerosis extent according to tertile of baseline AMH is depicted in Figure 1B . Monkeys with the lowest plasma AMH at baseline developed the most atherosclerosis 26 months later. To investigate the relationship between baseline AMH and subsequent atherosclerosis in each individual treatment group, monkeys were divided into two groups using the median of baseline AMH. Figure 1C shows that in all groups, baseline AMH seems to be related to atherosclerosis outcomes, although only the OVX group reached statistical significance. Finally, the negative correlation between baseline AMH and plaque area was also significant (r = j0.31, P G 0.01; Fig. 1D ). Neither AMH measured at the time of artery collection nor percentage change in AMH from baseline to posttreatment was significantly associated with plaque extent (P = 0.6 for both comparisons).
Plasma lipids correlate significantly with atherosclerosis
Plasma lipids measured at baseline (7 mo after beginning to consume a cholesterol-containing diet) correlated significantly with plaque area (TPC, r = 0.42, P G 0.001; LDL + VLDL-C, r = 0.46, P G 0.001; HDL-C r = j0.38, P = 0.002; and TPC/ HDL-C ratio, r = 0.44, P G 0.001). The correlations between lipids and atherosclerosis remained significant after 33 months of consuming the experimental diet (TPC, r = 0.70, P G 0.001; LDL + VLDL-C, r = 0.72, P G 0.001; HDL-C, r = j0.39, P = 0.001; and TPC/HDL-C ratio, r = 0.61, P G 0.001).
Baseline and post-OVX AMH, BW, E 2 , and plasma lipids AMH, BW, and plasma lipids were measured after consumption of the diet for 5 months (baseline) and 26 months after OVX. Follicular phase E 2 was measured at baseline only. The PRE and ROR groups were combined into a single PRE + ROR group (n = 49) for analysis because no baseline or posttreatment differences were observed between the two with respect to the aforementioned variables. There were no significant differences at baseline between monkeys assigned to the OVX (n = 18) or PRE + ROR (n = 49) conditions, respectively: AMH, 10.6 T 2 versus 13 T 1.3 ng/mL (P = 0.3); E 2 , 21.8 T 6 versus 25.5 T 4 pg/mL (P = 0.6); BW, 2.99 T 0.1 versus 3.15 T 0.1 kg (P = 0.3); TPC, 241.7 T 13 versus 238.1 T 7.9 mg/dL (P = 0.8); HDL-C, 45.3 T 3.5 versus 43.9 T 2.1 mg/dL (P = 0.7); LDL + VLDL-C, 196.4 T 14.5 versus 193.5 T 9 mg/dL (P = 0.9); and TPC/HDL-C ratio, 6.0 T 0.7 versus 6.1 T 0.4 (P = 0.9). Four months post-OVX, AMH was below the level of detection. After 26 months, no significant differences were observed between the OVX and PREMENOP monkeys, respectively, in BW (3.14 T 0.2 vs 3.46 T 0.12 kg; P = 0.2), TPC (318.2 T 86 vs 300.3 T 71 mg/dL; P = 0.4), HDL-C (46.7T 17 vs 45.9 T 19 mg/dL; P = 0.9), LDL + VLDL-C (271.6 T 19.5 vs 254.5 T 12 mg/dL; P = 0.5), and TPC/HDL-C (7.8 T 3 vs 7.6 T 3, P = 0.9). Similarly, baseline plasma lipids, BW, and E 2 and posttreatment plasma lipids and BW did not differ according to baseline AMH tertile (Table 1) .
DISCUSSION
In the present study, there was no effect of OVX or ROR on atherosclerosis extent when compared with premenopausal control monkeys. This finding was unexpected given previous reports of increased CHD risk after oophorectomy in both monkeys and women. 25, 26 However, the current study differs CHD, coronary heart disease; AMH, antimüllerian hormone; NA, not applicable; TPC, total plasma cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; VLDL-C, very-low-density lipoprotein cholesterol. from previous monkey studies because each treatment condition was balanced for plasma AMH (a previously validated marker of ovarian reserve or reproductive age) before the intervention. Consequently, we investigated retrospectively the potential relationship between AMH and subsequent atherosclerosis development. As a result, we found that AMH, measured before long-term (26 mo) consumption of an atherogenic diet, was negatively correlated with atherosclerosis extent and there was a significant, monotonic increase in atherosclerosis extent across tertiles of baseline AMH. Furthermore, within each individual treatment group, monkeys that fell below the median AMH at baseline developed more atherosclerosis than did those that fell above the median. Interestingly, it was only in the OVX group that this finding reached statistical significance. There were no differences in plasma lipids or lipoproteins among the tertiles of AMH, either at baseline or at the time of atherosclerosis measurement, indicating that the observed relationships between AMH and subsequent atherosclerosis were independent of plasma lipids. Taken together, these data suggest that AMH may be a marker of arterial susceptibility to atherosclerosis, a finding that may have been worsened by OVX. Consistent with some studies of women, however, the data also indicate that the trajectory of atherosclerosis progression was not influenced by estrogen depletion (OVX) compared with premenopausal women.
The observed relationship between low AMH and subsequent atherosclerosis development in premenopausal monkeys may relate to arterial estrogen exposure before initiation of the atherogenic diet. That is, AMH may be a marker of arterial susceptibility to atherosclerosis rather than having a direct relationship with atherosclerosis progression. It is well accepted that estrogen is atheroprotective through increased vascular responsiveness, attenuation of inflammatory mediators and cytokines, and decreased oxidative stress. 27 In addition, estrogen inhibits smooth muscle cell proliferation and reduces cholesterol and macrophage influx into the artery wall. 28 AMH is produced by the granulosa cells of small growing ovarian follicles (primary, secondary, and small preantral) and is highly correlated with larger antral follicle numbers. 29, 30 Waves of growing and antral follicles are responsible for most E 2 production by the ovary during the menstrual cycle. Consequently, lower AMH may indicate lower overall E 2 production. In support of this hypothesis are the results of a study of premenopausal women older than 40 years in whom peak E 2 was observed to be lowest in women who were also in the lowest tertile of AMH. 31 In addition, it has been reported that premenopausal women with diminished ovarian reserve (and probably low AMH) had impaired urinary excretions of estrone conjugate. 32 Taken together, these data indicate that it is possible that the monkeys in our study that were in the lowest tertile of AMH before dietary challenge may have had a history of chronically lower estrogen levels, resulting in increased susceptibility to initiation and progression of atherosclerosis. In addition, if AMH is a marker of E 2 exposure and subsequent artery susceptibility to the initiation of atherosclerosis, then it is not surprising that experimental reduction of AMH via chemical or surgical means was not associated with atherosclerosis extent.
We were not able to confirm a relationship between baseline E 2 and atherosclerosis in this study. This finding might be explained in relation to the E 2 sampling time period. Monkeys were sampled within È5 months of arrival at our center from Indonesia, and follicular phase samples were collected from two menstrual cycles only (one sample each cycle). Cynomolgus monkeys are known to experience hypothalamic suppression of menstrual cyclicity and cyclic hormones (E 2 , progesterone) after extreme stressors, such as travel and introduction to new social groups. 6, 33 Therefore, our sampling method may not adequately represent premenopausal E 2 exposure and, thus, degree of preexisting atheroprotection. More frequent measures of E 2 across numerous menstrual cycles, over a longer period (12-18 mo), may be required for accurate determinations of preexisting E 2 status.
Another potential explanation for our finding may relate to arterial aging. AMH is a marker of reproductive aging and is becoming accepted as a tool for predicting time to menopause. A recent long-term follow-up study of normo-ovulatory women reported that women with low AMH for their age became menopausal earlier than did those in the higher percentiles of AMH. 34 It is possible that ovarian aging and somatic aging occur in parallel and that AMH is also a marker for generalized aging. Studies in rodents indicate that estrogen's vasoprotective and anti-inflammatory effects are diminished in aging arteries of OVX older rats compared with young OVX rats. 35 It is also possible that circulating proinflammatory mediators increase with age, irrespective of E 2 production, resulting in increased arterial susceptibility to atherosclerosis.
36<38
It is notable that atherosclerosis extent was not increased in OVX monkeys compared with premenopausal control subjects. It is unclear how this observation may or may not be in contrast to some previous studies dealing with the effect of OVX on atherosclerosis progression. Monkeys in the study presented here consumed an atherogenic diet for 7 months before OVX, and from historical studies, we expected them to have developed small fibrofatty plaques by this time. 39 The amount of cholesterol in the atherogenic diet and the length of time the monkeys consumed the diet before OVX may modulate the effect of estrogen depletion on atherosclerosis progression. That is, it is possible that the trajectory for atherosclerosis progression was set and was not further exacerbated by estrogen depletion, except in monkeys that had low AMH before OVX. Nevertheless, this finding would seem to be in contrast to a previous cynomolgus monkey study that observed increased coronary artery atherosclerosis in OVX monkeys compared with premenopausal monkeys. 25 Interestingly, OVX monkeys in that study did not differ in atherosclerosis extent from premenopausal female monkeys classified as socially stressed (subordinate) and anovulatory (progesterone values below expected for ovulatory cycles). Thus, the main driver of atherosclerosis protection in that study was dominant social status, a finding reported previously to be associated with normal ovarian function. 6 There was no effect of social status on atherosclerosis in the present study. In contrast to the aforementioned study, findings from the present study are supported by a nonhuman primate experiment that included both premenopausal and OVX groups fed an amount of cholesterol in the diet (0. 28 mg cholesterol/cal) similar to our study, for a similar amount of time (30 mo). 40 In that study, no significant differences in coronary artery atherosclerosis were observed between OVX and premenopausal monkeys (0.20 T 0.04 vs 0.11 T 0.04, P 9 0.05).
There are limitations to this study that deserve mention. First, our hypothesis was not formulated a priori. As such, these findings should be viewed as retrospective and therefore preliminary until tested prospectively. Second, we know from historical studies 41 that cynomolgus macaques do not develop significant coronary artery atherosclerosis while consuming low-cholesterol diets (ie, in the wild or at the Indonesian Primate Center), and, therefore, it is assumed that the monkeys in this study did not have significant iliac artery atherosclerosis at the time of diet initiation. However, arterial function can be compromised in the absence of atherosclerosis (ie, arterial stiffness), and thus, other baseline measures of arterial function (ie, pulse wave velocity, in vitro vascular reactivity of arteries taken via biopsy, arterial gene expression) might have been informative and should be studied prospectively. Finally, AMH is not perfectly correlated with follicle numbers, and the coefficient of variation can be large. However, AMH was measured three times at baseline and approximately every 6 months posttreatment (data not shown), and the interindividual variation across time in premenopausal monkeys was less than 10% overall when the samples were assayed together in a single batch, thus giving us confidence that baseline AMH was representative of ovarian reserve in our monkeys.
CONCLUSIONS
In conclusion, our primary findings indicate that a relationship exists between a marker of ovarian reserve (AMH) and atherosclerosis progression in monkeys. This relationship is independent of the strong association between plasma lipid concentrations and atherosclerosis. This finding may have implications for CHD risk determination and early prevention in women who are of late reproductive age or transitioning to menopause.
